Dihydropyrimidine dehydrogenase modulates immune response to checkpoint inhibition in mismatch repair deficient/microsatellite instability-high colorectal cancer.
Understanding why some colorectal cancer patients resist immunotherapy opens paths toward new combination treatments for resistant cases.
Treatment with immune checkpoint inhibitors (ICIs) has radically improved outcomes for patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). Intrinsic and acquired resistance, however, remains an important concern.
What the study was
- Study design
- Retrospective Observational
- Population
- Adult patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Score 7/10: Retrospective Observational, mixed model, Exploratory; flag=NOVEL_TREATMENT
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.